摘要
目的探讨伊立替康+奥沙利铂+替吉奥治疗晚期胃癌对患者外周血血管内皮生长因子(vascular endothelial growth factor,VEGF)、循环肿瘤细胞(circulating tumor cells,CTC)水平及预后的影响。方法将2016年3月至2018年9月河南省肿瘤医院收治的89例晚期胃癌患者作为研究对象,以简单随机分组法将其分为对照组(44例)和观察组(45例),对照组给予伊立替康+替吉奥治疗,观察组采用伊立替康+奥沙利铂+替吉奥治疗,对比两组治疗效果,治疗前后外周血VEGF、CTC水平,不良反应及预后。结果观察组治疗有效率高于对照组(P<0.05);治疗后,观察组外周血VEGF、CTC水平均低于对照组,差异有显著性(P<0.05);观察组各毒副反应发生率与对照组比较,差异无显著性(P>0.05);观察组无进展生存时间(progress free survival,PFS)及总生存时间(overall survival,OS)均长于对照组,差异有显著性(P<0.05)。结论伊立替康+奥沙利铂+替吉奥治疗晚期胃癌患者疗效较好,可显著降低其外周血VEGF、CTC水平,改善患者预后,且未明显增加不良反应。
Objective To investigate the effect of irinotecan combined with oxaliplatin and tegafur on peripheral blood vascular endothelial growth factor(vascular endothelial growth factor,VEGF)and circulating tumor cells(circulating tumor cells,CTC)levels and the prognosis of patients with advanced gastric cancer.Method Eighty-nine patients with advanced gastric cancer who were admitted to the hospital between March 2016 and September 2018 were selected as the study subjects.They were divided into control group(n=44)and observation group(n=45)by the simple random grouping method.The control group were treated with irinotecan and tegafur.The observation group were treated with irinotecan combined with oxaliplatin and tegafur.The treatment effects,peripheral blood VEGF and CTC levels before and after treatment,adverse reactions and prognosis were compared between the two groups.Result The effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,peripheral blood VEGF and CTC level in the observation group were lower than those in the control group(P<0.05).There was no significant difference in the incidence rate of each toxic side effect between the two groups(P>0.05).The progression-free survival time(Progress free survival,PFS)and overall survival time(Overall survival,OS)of the observation group were longer than those of the control group(P<0.05).Conclusion Irinotecan combined with oxaliplatin and tegafur was effective in the treatment of patients with advanced gastric cancer.It could significantly reduce the VEGF and CTC levels in peripheral blood and improve the prognosis of patients,without significantly increasing adverse reactions.
作者
卢玖菊
徐伟春
张陈晨
陶丽
乔磊
Lu Jiuju;Xu Weichun;Zhang Chenchen;Tao Li;Qiao Lei(Department of Gastroenterology,Henan Cancer Hospital,Zhengzhou Henan 45008,China;Lymphatic Complex ward,Henan Cancer Hospital,Zhengzhou Henan 45008,China;不详)
出处
《中国临床医生杂志》
2020年第10期1172-1175,共4页
Chinese Journal For Clinicians
关键词
伊立替康
奥沙利铂
替吉奥
晚期胃癌
血管内皮生长因子
循环肿瘤细胞
Irinotecan
Oxaliplatin
Tegafur
Advanced gastric cancer
Vascular endothelial growth factor
Circulating tumor cells
